Background: Eribulin is a novel synthetic analogue of halichondrin B, which acts as a microtubule inhibitor by interacting with the microtubules and inhibits the G2-M growth phase. Eribulin was approved for metastatic breast cancer (MBC) based on landmark EMBRACE (phase-3) trial, although only a small number of Asian subgroups of the population were included, and data in the Indian subset of patients is limited. Therefore, in this real-world study we retrospectively assessed the clinical outcomes of eribulin in Indian women with metastatic breast cancer (heavily pre-treated). Methods: Adult MBC patients who had advanced following at least two chemotherapy lines, including anthracyclines and taxanes, in either an adjuvant or metastatic setting and were treated with eribulin over several lines were retrospectively analyzed. Records pertaining to socio-demographics, clinical, pathology, imaging, and therapy were reviewed. The overall survival (OS), progression-free survival (PFS), and tumor response were calculated. Results: A total of 80 patients were included. The median age of patients was 54.5 years (range: 27-82). Eribulin was majorly used as a second-line and third-line chemotherapy agent in 28 (35 percent) and 24 (30 percent) of MBC patients, respectively. In 57 evaluable patients, the best objective response rate (ORR) was 43.85 percent, while the clinical benefit rate was 59.65 percent with eribulin therapy. The median OS and PFS were 17.29 (95 percent CI: 14.31-20.27) and 11.76 (95 percent CI: 9.5-14.02) months, respectively. There was positive correlation between the number of cycles and the outcomes of survival, with patients getting more than 6 cycles having superior OS and PFS. On subgroup analysis, patients with liver metastasis had significantly (p<0.001) lower mean OS (9.42 months) and PFS (3.69 months) than other sites. Conclusions: This real-world retrospective study supports and confirms the efficacy of eribulin in Indian patients with MBC (heavily pre-treated). It should be considered in the strategy of several chemotherapy lines in MBC.